A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment

Evusheld(®) (tixagevimab + cilgavimab; AZD7442) was the first anti-Spike monoclonal antibody (mAb) cocktail designed not only for treatment but also with pre-exposure prophylaxis in mind. The immunoglobulins were engineered for prolonged half-life by modifying the Fc fragment, thus creating a long-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Focosi, Daniele, Casadevall, Arturo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505619/
https://www.ncbi.nlm.nih.gov/pubmed/36146805
http://dx.doi.org/10.3390/v14091999

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505619/
https://www.ncbi.nlm.nih.gov/pubmed/36146805
http://dx.doi.org/10.3390/v14091999

Ejemplares similares